Lymphomas Clinical Trial
Official title:
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
Background:
- Currently, National Cancer Institute treatment trials use clinical staff reporting to
monitor adverse side effects. The clinical staff reports draw on items from the Common
Terminology Criteria for Adverse Events (CTCAE).
- Several of the items in the CTCAE can be adapted for use in patient self-reporting of
side effects. Researchers are interested in developing a patient-reported outcome (PRO)
approach to the CTCAE.
Objectives:
- To develop questions that can be used to create a patient-reported outcome version of
the CTCAE (PRO-CTCAE).
- To evaluate patient comprehension of and test the usefulness of the PRO-CTCAE questions
among diverse groups of patients.
Eligibility:
- Individuals 18 years of age and older who are receiving chemotherapy or radiotherapy as
cancer treatment.
- Participants must be able to speak and understand English.
Design:
- Researchers will conduct up to three rounds of interviews with patients currently
receiving chemotherapy or radiation therapy treatments for cancer.
- Participants will be recruited independently from four different clinical treatment
sites. At least 25 percent of patients will have an educational attainment of high
school or less.
- Each patient will complete a two-part protocol, including a set of PROs that will be
followed by a series of questions to evaluate patient comprehension, memory, perceived
clarity, and judgment of the PROs.
- The research will be completed in approximately 1 hour, and participants will receive a
small amount of compensation for their time and participation.
Background:
The current approach to monitoring adverse symptom events in NCI-sponsored treatment trials
is clinical staff reporting, using items from the Common Terminology Criteria for Averse
Events (CTCAE). Of the 1,059 discrete items in the CTCAE, approximately 77 contain a
subjective component sufficient enough to be amenable to patient self-reporting such as pain,
fatigue, nausea,
and hair loss. There is general agreement that the patient, via a self-report, is the best
source for reporting symptoms. Studies have shown that when compared to clinician reports,
patients report earlier onset, greater severity, and longer duration of symptoms.
In September 2008, the NCI awarded a contract (N02-PC-85002-29; PI: Basch; Co-I: Hay) to
support the development of an electronic-based and psychometrically robust patient-reported
outcomes version of the symptom-related AEs listed in the CTCAE in an effort to improve the
accuracy and precision of grading of this class of AEs. To achieve this goal, we will conduct
cognitive interviews with 77 newly-developed PRO items that will subsequently be subjected to
psychometric analysis, usability testing, and feasibility testing in a range of treatment
settings among diverse groups of patients.
Objectives:
The overall goal of this proposed study is to evaluate patient comprehension of 77 newly
developed PRO items in a range of treatment settings among diverse groups of cancer patients.
The objectives are to evaluate: 1) patients understanding of the language and 2) the
usability of the technology interface for collecting the PRO data of the PRO-CTCAE system.
Eligibility:
Patients will be eligible for the study if they are 1) aged 18 or older; 2) English-fluent;
3) undergoing chemotherapy and/or radiotherapy with curative or palliative intent; and 4) can
provide informed consent.
Design:
We will conduct up to three rounds of cognitive interviews in 100 cancer patients at
participating cancer centers including MSKCC, Dana Farber Cancer Institute, Duke and M.D.
Anderson. After completion of the first round of interviews, results will be analyzed for
problematic items. Revised items will be reviewed in subsequent rounds as needed. The final
PRO-CTCAE items will proceed to usability testing. Usability testing will comprise three main
components: 1) observation of users interacting with the web-based assessment system coupled
with think aloud protocols and extensive field notes; 2) user feedback using semi-structured
interviews and short surveys; and 3) web analytics including tracking for different web
pages, with clickstream analysis. Usability testing will be conducted with 60 clinical
research staff and 60 patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01359982 -
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
|
Phase 1 | |
Completed |
NCT02140736 -
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
|
||
Completed |
NCT00725634 -
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00947739 -
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
Recruiting |
NCT02211755 -
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
|
Phase 1 | |
Completed |
NCT02048488 -
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT06148220 -
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
|
N/A | |
Withdrawn |
NCT02786485 -
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
|
Phase 1 | |
Completed |
NCT01387841 -
Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT00396864 -
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
|
Phase 1 | |
Terminated |
NCT00023166 -
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
|
Phase 1 | |
Recruiting |
NCT04417803 -
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
|
N/A | |
Recruiting |
NCT05775406 -
Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
|
Phase 1 | |
Recruiting |
NCT02274584 -
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01836822 -
Bronchoscopic Sampling Techniques in Sarcoidosis
|
N/A | |
Completed |
NCT02902237 -
tTF-NGR Phase I Study
|
Phase 1 | |
Completed |
NCT02578316 -
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
|
Phase 1 | |
Recruiting |
NCT00900198 -
Collection of Tissue Samples for Cancer Research
|
||
Completed |
NCT02740270 -
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
|
Phase 1 |